No detectable systemic absorption of topically applied 0.02% and 0.04% chlormethine (CL) gel in patients with mycosis-fungoides cutaneous T-cell lymphoma (MF-CTCL)

被引：0
|
作者：
Querfeld, C. [1 ]
Scarisbrick, J. [2 ]
Quaglino, P. [3 ]
Papadavid, E. [4 ]
Romero, P. Ortiz [5 ]
机构：
[1] City Hope Canc Ctr, Duarte, CA USA
[2] Univ Birmingham, Birmingham, W Midlands, England
[3] Univ Turin, Turin, Italy
[4] Attikon Univ Hosp, Athens, Greece
[5] Univ Complutense, Univ Hosp 12 Octubre, Madrid, Spain
来源：
JOURNAL OF INVESTIGATIVE DERMATOLOGY | 2020年 / 140卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
833
引用
收藏
页码：S109 / S109
页数：1
相关论文
共 50 条
  • [1] Management of mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL): focus on chlormethine gel
    Denis, Daphne
    Beneton, Nathalie
    Laribi, Kamel
    Maillard, Herve
    CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 2241 - 2251
  • [2] Schedule frequency of chlormethine gel for patients with mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL): A real-world evidence study
    Querfeld, Christiane
    Binder, Gary
    Turini, Marco
    Gor, Deval
    Wassel, Christina L.
    Pashos, Chris
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB77 - AB77
  • [3] Maintenance therapy with chlormethine gel among patients with mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL): a real-world evidence study
    Querfeld, Christiane
    Turini, Marco
    Gor, Deval
    Angello, James T.
    Pashos, Chris
    Kim, Ellen J.
    EUROPEAN JOURNAL OF CANCER, 2021, 156 : S45 - S45
  • [4] Efficacy and quality of life (QoL) in patients with mycosis fungoides cutaneous T-cell lymphoma (MF-CTCL) treated with chlormethine gel and other therapies: results from the PROVe study
    Kim, E. J.
    Geskin, L. J.
    Querfeld, C.
    Girardi, M.
    Mink, D. R.
    Williams, M. J.
    Angello, J. T.
    Bailey, W. L.
    EUROPEAN JOURNAL OF CANCER, 2019, 119 : S39 - S39
  • [5] Concomitant use of steroids or phototherapy with chlormethine gel among patients with mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL): a real-world evidence study
    Querfeld, Christiane
    Turini, Marco
    Gor, Deval
    Angello, James T.
    Pashos, Chris
    Kim, Ellen J.
    EUROPEAN JOURNAL OF CANCER, 2021, 156 : S44 - S45
  • [6] Efficacy of chlormethine gel in patients with stage I-IIA mycosis fungoides cutaneous T-cell lymphoma (MF-CTCL): re-analysis of a randomized phase 2 study
    Kim, E. J.
    Geskin, L. J.
    Mink, D.
    Williams, M.
    Angello, J.
    Bailey, W.
    Kim, Y.
    EUROPEAN JOURNAL OF CANCER, 2019, 119 : S30 - S30
  • [7] Clinician-level variation in mechlorethamine treatment duration in mycosis fungoides cutaneous T-cell lymphoma (MF-CTCL)
    Querfeld, Christian
    Pacheco, Theresa
    Haverkos, Bradley
    Binder, Gary
    Angello, James
    Poligone, Brian
    EUROPEAN JOURNAL OF CANCER, 2019, 119 : S8 - S8
  • [8] MYCOSIS-FUNGOIDES - CUTANEOUS T-CELL LYMPHOMA
    ZAIM, MT
    GRINKEMEYER, MD
    AMERICAN FAMILY PHYSICIAN, 1991, 43 (05) : 1703 - 1707
  • [9] Maintenance and Concomitant Therapy Use with Chlormethine Gel Among Patients with Stage IA/IB Mycosis Fungoides-Type Cutaneous T-Cell Lymphoma (MF-CTCL): A Real-World Evidence Study
    Querfeld, Christiane
    Nelson, Winnie W.
    Gor, Deval
    Pashos, Chris L.
    Doan, Quan, V
    Turini, Marco
    Angello, James T.
    Geskin, Larisa J.
    DERMATOLOGY AND THERAPY, 2022, 12 (12) : 2781 - 2795
  • [10] Mechlorethamine Hydrochloride Gel in the Treatment of Mycosis Fungoides-Type Cutaneous T-Cell Lymphoma (MF-CTCL): A Focus on Patient Selection and Special Considerations
    Crimp, Caitlin
    Gangal, Ameya
    Tarabadkar, Erica S.
    Shinohara, Michi M.
    CANCER MANAGEMENT AND RESEARCH, 2022, 14 : 3271 - 3279
12345